MiR-202-5p/PTEN mediates doxorubicin-resistance of breast cancer cells via PI3K/Akt signaling pathway

References

• He Y, Ding J, Lin Y, Li J, Shi Y, Wang J, Zhu Y, Wang K, Hu X. Gambogenic acid alters chemosensitivity of breast cancer cells to Adriamycin. BMC Complement Altern Med: 2015;15:181. doi:10.1186/s12906-015-0710-8.
   PubMed Web of Science ®Google Scholar
• Yu ZG, Jia CX, Liu LY, Geng CZ, Tang JH, Zhang J, Zhang Q, Li YY, Ma ZB. The prevalence and correlates of breast cancer among women in Eastern China. PLoS One: 2012;7:e37784. doi:10.1371/journal.pone.0037784.
   PubMed Web of Science ®Google Scholar
• Miao Y, Zheng W, Li N, Su Z, Zhao L, Zhou H, Jia L. MicroRNA-130b targets PTEN to mediate drug resistance and proliferation of breast cancer cells via the PI3K/Akt signaling pathway. Sci Rep: 2017;7:41942. doi:10.1038/srep41942.
   PubMed Web of Science ®Google Scholar
• Chen Y, Sun Y, Chen L, Xu X, Zhang X, Wang B, Min L, Liu W. miRNA-200c increases the sensitivity of breast cancer cells to doxorubicin through the suppression of E-cadherin-mediated PTEN/Akt signaling. Mol Med Rep: 2013;7:1579–1584. doi:10.3892/mmr.2013.1403.
   PubMed Web of Science ®Google Scholar
• Joosse SA, Muller V, Steinbach B, Pantel K, Schwarzenbach H. Circulating cell-free cancer-testis MAGE-A RNA, BORIS RNA, let-7b and miR-202 in the blood of patients with breast cancer and benign breast diseases. Br J Cancer: 2014;111:909–917. doi:10.1038/bjc.2014.360.
   PubMed Web of Science ®Google Scholar
• Yuan Y, Anbalagan D, Lee LH, Samy RP, Shanmugam MK, Kumar AP, Sethi G, Lobie PE, Lim LH. ANXA1 inhibits miRNA-196a in a negative feedback loop through NF-kB and c-Myc to reduce breast cancer proliferation. Oncotarget: 2016;7:27007–27020. doi:10.18632/oncotarget.8875.
   PubMedGoogle Scholar
• Li P, Xie XB, Chen Q, Pang GL, Luo W, Tu JC, Zheng F, Liu SM, Han L, Zhang JK, et al. MiRNA-15a mediates cell cycle arrest and potentiates apoptosis in breast cancer cells by targeting synuclein-gamma. Asian Pac J Cancer Prev: 2014;15:6949–6954.
   PubMedGoogle Scholar
• Yang L, Li Q, Wang Q, Jiang Z, Zhang L. Silencing of miRNA-218 promotes migration and invasion of breast cancer via Slit2-Robo1 pathway. Biomed Pharmacother: 2012;66:535–540. doi:10.1016/j.biopha.2012.04.006.
   PubMed Web of Science ®Google Scholar
• Kastl L, Brown I, Schofield AC. miRNA-34a is associated with docetaxel resistance in human breast cancer cells. Breast Cancer Res Treat: 2012;131:445–454. doi:10.1007/s10549-011-1424-3.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Li C, Wang M, Su L, Qu Y, Li J, Yu B, Yan M, Yu Y, Liu B, et al.. Decrease of miR-202-3p expression, a novel tumor suppressor, in gastric cancer. PLoS One: 2013;8:e69756. doi:10.1371/journal.pone.0069756.
   PubMed Web of Science ®Google Scholar
• Li YG, He JH, Yu L, Hang ZP, Li W, Shun WH, Huang GX. microRNA202 suppresses MYCN expression under the control of E2F1 in the neuroblastoma cell line LAN5. Mol Med Rep: 2014;9:541–546. doi:10.3892/mmr.2013.1845.
   PubMed Web of Science ®Google Scholar
• Shen H, Wang D, Li L, Yang S, Chen X, Zhou S, Zhong S, Zhao J, Tang J. MiR-222 promotes drug-resistance of breast cancer cells to adriamycin via modulation of PTEN/Akt/FOXO1 pathway. Gene: 2017;596:110–118. doi:10.1016/j.gene.2016.10.016.
   PubMed Web of Science ®Google Scholar
• Zheng L, Zhang Y, Liu Y, Zhou M, Lu Y, Yuan L, Zhang C, Hong M, Wang S, Li X. MiR-106b induces cell radioresistance via the PTEN/PI3K/AKT pathways and p21 in colorectal cancer. J Transl Med: 2015;13:252. doi:10.1186/s12967-015-0592-z.
   PubMed Web of Science ®Google Scholar
• Wu ZH, Tao ZH, Zhang J, Li T, Ni C, Xie J, Zhang JF, Hu XC. MiRNA-21 induces epithelial to mesenchymal transition and gemcitabine resistance via the PTEN/AKT pathway in breast cancer. Tumour Biol: 2016;37:7245–7254. doi:10.1007/s13277-015-4604-7.
   PubMedGoogle Scholar
• Shen X, Guo Y, Qi J, Shi W, Wu X, Ni H, Ju S. Study on the association between miRNA-202 expression and drug sensitivity in multiple myeloma cells. Pathol Oncol Res: 2016;22:531–539. doi:10.1007/s12253-015-0035-4.
   PubMed Web of Science ®Google Scholar
• Chao A, Lai CH, Chen HC, Lin CY, Tsai CL, Tang YH, Huang HJ, Lin CT, Chen MY, Huang KG, et al. Serum microRNAs in clear cell carcinoma of the ovary. Taiwan J Obstet Gynecol: 2014;53:536–541. doi:10.1016/j.tjog.2014.07.005.
   PubMed Web of Science ®Google Scholar
• Wang F, Li L, Chen Z, Zhu M, Gu Y. MicroRNA-214 acts as a potential oncogene in breast cancer by targeting the PTEN-PI3K/Akt signaling pathway. Int J Mol Med: 2016;37:1421–1428. doi:10.3892/ijmm.2016.2518.
   PubMed Web of Science ®Google Scholar
• Zhong S, Li W, Chen Z, Xu J, Zhao J. MiR-222 and miR-29a contribute to the drug-resistance of breast cancer cells. Gene: 2013;531:8–14. doi:10.1016/j.gene.2013.08.062.
   PubMed Web of Science ®Google Scholar
• Feng X, Zhao L, Gao S, Song X, Dong W, Zhao Y, Zhou H, Cheng L, Miao X, Jia L. Increased fucosylation has a pivotal role in multidrug resistance of breast cancer cells through miR-224-3p targeting FUT4. Gene: 2016;578:232–241. doi:10.1016/j.gene.2015.12.028.
   PubMed Web of Science ®Google Scholar
• Lin Z, Song D, Wei H, Yang X, Liu T, Yan W, Xiao J. TGF-beta1-induced miR-202 mediates drug resistance by inhibiting apoptosis in human osteosarcoma. J Cancer Res Clin Oncol: 2016;142:239–246. doi:10.1007/s00432-015-2028-9.
   PubMed Web of Science ®Google Scholar
• Wang Q, Huang Z, Guo W, Ni S, Xiao X, Wang L, Huang D, Tan C, Xu Q, Zha R, et al. microRNA-202-3p inhibits cell proliferation by targeting ADP-ribosylation factor-like 5A in human colorectal carcinoma. Clin Cancer Res: 2014;20:1146–1157. doi:10.1158/1078-0432.CCR-13-1023.
   PubMed Web of Science ®Google Scholar
• Slomovitz BM, Coleman RL. The PI3K/AKT/mTOR pathway as a therapeutic target in endometrial cancer. Clin Cancer Res: 2012;18:5856–5864. doi:10.1158/1078-0432.CCR-12-0662.
   PubMed Web of Science ®Google Scholar
• Moon SH, Kim DK, Cha Y, Jeon I, Song J, Park KS. PI3K/Akt and Stat3 signaling regulated by PTEN control of the cancer stem cell population, proliferation and senescence in a glioblastoma cell line. Int J Oncol: 2013;42:921–928. doi:10.3892/ijo.2013.1765.
   PubMed Web of Science ®Google Scholar